Neurocognition in Early-Onset Schizophrenia and Schizoaffective Disorders

 The Treatment of Early Onset Schizophrenia Spectrum (TEOSS) project was conducted with grant support from the National Institute of Mental Health under cooperative agreements U01MH61528 to the University of North Carolina (P.I.: Lin Sikich), U01MH61464 to the University of Washington (P.I.: Jon McClellan), U01MH62726 to Harvard Medical School (P.I.: Jean Frazier), and U01MH61355 to Case Western Reserve University (P.I.: Robert Findling), and by the Maternal Child Health Bureau (#MCJ379154A), and the Administration on Developmental Disabilities (#90DD043003). The research was conducted in NIH supported Clinical Research Centers at Seattle Children's Hospital, University of Washington (M01-RR-00037) and the University of North Carolina (M01-RR00046).

 The opinions and assertions contained in this report are the private views of the authors and are not to be construed as official or as reflecting the views of the Department of Health and Human Services, the National Institutes of Health, or the National Institute of Mental Health.

 Disclosure: Dr. Hooper receives or has received research support or served as a speaker/consultant for Eli Lilly and Sanofi-Aventis. Dr. Youngstrom has previously served on the Data Safety and Monitoring Board for Eli Lilly and consulted in the past with Otsuka. Dr. Sikich has a current financial interest and receives research funding or participates in clinical trials with Janssen, Pfizer, Bristol Myers-Squibb, Neuropharm, Curemark, and Seaside Pharmaceuticals. She also received software for a computer intervention in schizophrenia from Posit Science. In the past, Dr. Sikich received research funding from Eli Lilly, Janssen, Pfizer, Otsuka, and Astra Zeneca, and has served as a consultant for Sanofi Aventis and ABT Associates. Dr. Frazier receives or has received research support and acted as a consultant for Bristol-Myers Squibb Company, Eli Lilly, GlaxoSmithKline, Johnson & Johnson, Neuropharm, Otsuka America Pharmaceutical, and Pfizer. Dr. Findling receives or has received research support, acted as a consultant, and/or served on a speaker's bureau for Abbott, Addrenex, AstraZeneca, Biovail, Bristol-Myers Squibb, Forest, GlaxoSmithKline, Johnson & Johnson, KemPharm, Eli Lilly, Lundbeck, Neuropharm, Novartis, Organon, Otsuka, Pfizer, Sanofi-Aventis, Sepracore, Shire, Solvay, Supernus Pharmaceuticals, Validus, and Wyeth. Dr. McClellan has had past research support from Pfizer. Dr. Hamer has served as a consultant or advisor for Acadia, Cenerx, Corcept, Epix, Johnson & Johnson, NeuroPharmaBoost, Pepper-Hamilton, PureTechVentures, Sanofi-Aventis, and Takeda. He has served on the advisory board for Enabled MD, Novartis, and Wyeth. He has served on a Data Safety Monitoring Board (DSMB) for Allergan, Eli Lilly & Company, Pfizer, Schwartz, and Solvey. He has served on a Mock Advisory Panel for Alpharma. He has served as a statistician on a University of North Carolina contract for a clinical trial with AstraZeneca. He has taught several seminars for SAS Institute. He has served as an expert witness for Winston-Strawn. He or his wife own stock in Bristol-Myers Squibb, Amgen, Eli Lilly & Company, Genentech, Proctor & Gamble, and Sepracor. Dr. Lieberman serves as a consultant and/or advisor for Astra Zeneca, Bioline, Eli Lilly, Forest Laboratories, GlaxoSmithKline, Pfizer, and Wyeth; and as a member of the Data Safety Monitoring Board (DSMB) for Solvay. He does not receive financial compensation or salary support for this participation as a consultant or as a member of a board. He receives grant support from AstraZeneca, Allon, Bristol-Myers Squibb, Cephalon, GlaxoSmithKline, Janssen, Merck, Pfizer, and Wyeth; and he holds a patent from Repligen. Drs. Guiliano, Breiger, and Vitiello report no biomedical financial interests or potential conflicts of interest.

PII: S0890-8567(09)00013-6

doi:10.1016/j.jaac.2009.11.001

© 2010 American Academy of Child and Adolescent Psychiatry. Published by Elsevier Inc. All rights reserved.